Health Products Regulation at Duke-NUS 2026

As part of ongoing efforts to build public understanding of how radiopharmaceuticals are regulated, Mr Tay Kiat Boon, QA Lead at the Clinical Imaging Research Centre (CIRC), was recently invited to speak at the GMS5003 module on Health Products Regulation at Duke-NUS Medical School.

The session gave students and future healthcare professionals a closer look at the regulatory framework governing radiopharmaceuticals, from GMP-compliant sterile manufacturing and batch release, to the additional layers of oversight that come with working with short-half-life, radioactive therapeutic and diagnostic agents such as ⁶⁸Ga, ¹⁸F, ¹⁷⁷Lu, and ²²⁵Ac.

Beyond the technical detail, the session’s broader aim was public education: helping the next generation of clinicians, scientists, and policymakers understand why radiopharmaceutical regulation looks the way it does, and how frameworks like PIC/S and ICH guidelines translate into the safe, timely delivery of these products to patients.

Engagements like this reflect CIRC’s continued commitment to regulatory transparency and to strengthening the pipeline of talent entering Singapore’s nuclear medicine and radiopharmaceutical sector.